EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interferon‐gamma contributes to disease progression in the Ndufs4 (−/−) model of Leigh syndrome

Allison R Hanaford, Asheema Khanna, Katerina James, Vivian Truong, Ryan Liao, Yihan Chen, Michael Mulholland, Ernst-Bernhard Kayser, Kino Watanabe, Erin Shien Hsieh, Margaret Sedensky, Philip G Morgan und 3 weitere

Neuropathology and Applied Neurobiology · 2024

DOI: 10.1111/nan.12977 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2024. Verfasst von Allison R Hanaford und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Disease Progression, Electron Transport Complex I, Interferon-gamma, Leigh Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US National Institutes of Health, Northumbria University Internal Funding, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Leigh syndrome (LS), the most common paediatric presentation of genetic mitochondrial dysfunction, is a multi‐system disorder characterised by severe neurologic and metabolic abnormalities. Symmetric, bilateral, progressive necrotizing lesions in the brainstem are defining features of the disease. Patients are often symptom free in early life but typically develop symptoms by about 2 years of age. The mechanisms underlying disease onset and progression in LS remain obscure. Recent studies have shown that the immune system causally drives disease in the Ndufs4 (−/−) mouse model of LS: treatment of Ndufs4 (−/−) mice with the macrophage‐depleting Csf1r inhibitor pexidartinib prevents disease. While the precise mechanisms leading to immune activation and immune factors involved in disease progression have not yet been determined, interferon‐gamma (IFNγ) and interferon gamma‐induced protein 10 (IP10) were found to be significantly elevated in Ndufs4 (−/−) brainstem, implicating these factors in disease. Here, we aimed to explore the role of IFNγ and IP10 in LS.

Methods

To establish the role of IFNγ and IP10 in LS, we generated IFNγ and IP10 deficient Ndufs4 (−/−)/ Ifng (−/−) and Ndufs4 (−/−)/ IP10 (−/−) double knockout animals, as well as IFNγ and IP10 heterozygous, Ndufs4 (−/−)/ Ifng (+/−) and Ndufs4 (−/−)/ IP10 (+/−), animals. We monitored disease onset and progression to define the impact of heterozygous or homozygous loss of IFNγ and IP10 in LS.

Results

Loss of IP10 does not significantly impact the onset or progression of disease in the Ndufs4 (−/−) model. IFNγ loss significantly extends survival and delays disease progression in a gene dosage‐dependent manner, though the benefits are modest compared to Csf1r inhibition.

Conclusions

IFNγ contributes to disease onset and progression in LS. Our findings suggest that IFNγ targeting therapies may provide some benefits in genetic mitochondrial disease, but targeting IFNγ alone would likely yield only modest benefits in LS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease ProgressionElectron Transport Complex IInterferon-gammaLeigh DiseaseAnimalsMiceBrain StemDisease Models, AnimalMice, Inbred C57BLMice, Knockout

Stichwörter der Autor:innen

Leigh diseasechemokine CXCL10interferon‐gammamitochondrial diseases

Substanzen

Electron Transport Complex IInterferon-gammaNdufs4 protein, mouse

Autor:innen und Institutionen

  • Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Department of Anaesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
  • Department of Paediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Department of Neurology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Simon C Johnson

Förderung

  • US National Institutes of Health
  • Northumbria University Internal Funding
  • NIGMS NIH HHS
  • Northwest Mitochondrial Research Guild
  • NIA NIH HHS
  • NIAID NIH HHS
  • Academy of Medical Sciences (UK) Professorship
  • NINDS NIH HHS

Zitieren

APA

Hanaford, A. R., Khanna, A., James, K., Truong, V., Liao, R., Chen, Y., Mulholland, M., Kayser, E. B., Watanabe, K., Hsieh, E. S., Sedensky, M., Morgan, P. G., Kalia, V., Sarkar, S., & Johnson, S. C. (2024). Interferon‐gamma contributes to disease progression in the Ndufs4 (−/−) model of Leigh syndrome. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.12977

Vancouver

Hanaford AR, Khanna A, James K, Truong V, Liao R, Chen Y, et al. Interferon‐gamma contributes to disease progression in the Ndufs4 (−/−) model of Leigh syndrome. Neuropathology and Applied Neurobiology. 2024. doi:10.1111/nan.12977

BibTeX
@article{Hanaford2024,
  author = {Hanaford, Allison R and Khanna, Asheema and James, Katerina and Truong, Vivian and Liao, Ryan and Chen, Yihan and Mulholland, Michael and Kayser, Ernst-Bernhard and Watanabe, Kino and Hsieh, Erin Shien and Sedensky, Margaret and Morgan, Philip G and Kalia, Vandana and Sarkar, Surojit and Johnson, Simon C},
  title = {Interferon‐gamma contributes to disease progression in the Ndufs4 (−/−) model of Leigh syndrome},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2024},
  doi = {10.1111/nan.12977}
}
Kostenlos starten →